TCBP Operating Income vs Other Operating Expenses Analysis

TCBP Stock

USD 1.95 0.22 10.14%

TC BioPharm financial indicator trend analysis is much more than just breaking down TC BioPharm Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether TC BioPharm Holdings is a good investment. Please check the relationship between TC BioPharm Operating Income and its Other Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Operating Income vs Other Operating Expenses

Operating Income vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of TC BioPharm Holdings Operating Income account and Other Operating Expenses. At this time, the significance of the direction appears to have strong relationship.

The correlation between TC BioPharm's Operating Income and Other Operating Expenses is 0.73. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of TC BioPharm Holdings, assuming nothing else is changed. The correlation between historical values of TC BioPharm's Operating Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of TC BioPharm Holdings are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Operating Income i.e., TC BioPharm's Operating Income and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from TC BioPharm Holdings operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of TC BioPharm Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of TC BioPharm Holdings. It is also known as TC BioPharm overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from TC BioPharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into TC BioPharm Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

As of 03/01/2025, Tax Provision is likely to drop to about (1 M). In addition to that, Selling General Administrative is likely to drop to about 5.1 M

	2022	2024	2025 (projected)
Depreciation And Amortization	762.5K	567.1K	638.0K
Interest Income	2.2K	2.0K	1.9K

Depreciation And Amortization Interest Income

TC BioPharm fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.45	-0.3	-0.35	0.48	0.29	0.55	0.18	-0.18	-0.5	0.18	-0.2	0.31	0.17	-0.44	0.31	0.49	-0.05	0.13	0.05	-0.54	0.46	0.24	-0.29	0.42	-0.04
Short Long Term Debt Total	-0.45		0.58	0.82	-0.94	-0.2	-0.99	-0.01	0.33	0.96	-0.11	0.1	-0.14	-0.01	0.68	-0.14	-0.09	-0.3	0.01	0.17	0.11	-0.48	-0.22	0.91	-0.81	0.13
Other Current Liab	-0.3	0.58		0.92	-0.38	-0.8	-0.54	-0.67	-0.46	0.35	-0.75	0.47	0.63	-0.67	0.92	0.63	-0.7	0.27	-0.71	-0.55	0.71	-0.48	0.42	0.41	-0.15	-0.54
Total Current Liabilities	-0.35	0.82	0.92		-0.63	-0.63	-0.78	-0.49	-0.2	0.66	-0.59	0.41	0.35	-0.49	0.92	0.35	-0.51	0.14	-0.51	-0.32	0.52	-0.39	0.28	0.67	-0.4	-0.4
Total Stockholder Equity	0.48	-0.94	-0.38	-0.63		-0.07	0.96	-0.27	-0.6	-0.96	-0.19	0.2	0.36	-0.28	-0.45	0.36	-0.13	0.57	-0.29	-0.45	0.09	0.62	0.54	-0.95	0.96	-0.38
Other Liab	0.29	-0.2	-0.8	-0.63	-0.07		0.16	0.97	0.81	0.04	0.96	-0.85	-0.78	0.96	-0.85	-0.78	0.94	-0.68	0.96	0.91	-0.93	0.14	-0.74	0.14	-0.32	0.67
Net Tangible Assets	0.55	-0.99	-0.54	-0.78	0.96	0.16		-0.03	-0.4	-0.97	0.06	-0.06	0.23	-0.03	-0.64	0.23	0.1	0.32	-0.06	-0.22	-0.13	0.53	0.31	-0.91	0.85	-0.16
Property Plant And Equipment Net	0.18	-0.01	-0.67	-0.49	-0.27	0.97	-0.03		0.9	0.2	0.98	-0.9	-0.78	1.0	-0.73	-0.78	0.93	-0.84	0.99	0.98	-0.91	-0.09	-0.87	0.32	-0.52	0.76
Current Deferred Revenue	-0.18	0.33	-0.46	-0.2	-0.6	0.81	-0.4	0.9		0.55	0.88	-0.75	-0.87	0.91	-0.44	-0.87	0.74	-0.85	0.93	0.96	-0.71	-0.3	-0.95	0.57	-0.8	0.78
Net Debt	-0.5	0.96	0.35	0.66	-0.96	0.04	-0.97	0.2	0.55		0.11	-0.05	-0.42	0.2	0.48	-0.42	0.08	-0.4	0.23	0.38	-0.05	-0.41	-0.41	0.92	-0.89	0.27
Retained Earnings	0.18	-0.11	-0.75	-0.59	-0.19	0.96	0.06	0.98	0.88	0.11		-0.87	-0.78	0.98	-0.79	-0.78	0.89	-0.81	0.99	0.94	-0.89	-0.07	-0.87	0.2	-0.45	0.77
Accounts Payable	-0.2	0.1	0.47	0.41	0.2	-0.85	-0.06	-0.9	-0.75	-0.05	-0.87		0.56	-0.9	0.67	0.56	-0.79	0.83	-0.84	-0.88	0.76	0.3	0.81	-0.29	0.43	-0.61
Cash	0.31	-0.14	0.63	0.35	0.36	-0.78	0.23	-0.78	-0.87	-0.42	-0.78	0.56		-0.78	0.52	1.0	-0.6	0.51	-0.83	-0.82	0.58	-0.06	0.76	-0.31	0.54	-0.59
Non Current Assets Total	0.17	-0.01	-0.67	-0.49	-0.28	0.96	-0.03	1.0	0.91	0.2	0.98	-0.9	-0.78		-0.72	-0.78	0.92	-0.85	0.99	0.98	-0.91	-0.11	-0.88	0.32	-0.53	0.78
Non Currrent Assets Other	-0.44	0.68	0.92	0.92	-0.45	-0.85	-0.64	-0.73	-0.44	0.48	-0.79	0.67	0.52	-0.72		0.52	-0.74	0.36	-0.72	-0.59	0.75	-0.34	0.45	0.4	-0.18	-0.45
Cash And Short Term Investments	0.31	-0.14	0.63	0.35	0.36	-0.78	0.23	-0.78	-0.87	-0.42	-0.78	0.56	1.0	-0.78	0.52		-0.6	0.51	-0.83	-0.82	0.58	-0.06	0.76	-0.31	0.54	-0.59
Net Receivables	0.49	-0.09	-0.7	-0.51	-0.13	0.94	0.1	0.93	0.74	0.08	0.89	-0.79	-0.6	0.92	-0.74	-0.6		-0.74	0.91	0.87	-1.0	0.13	-0.65	0.23	-0.35	0.7
Common Stock Shares Outstanding	-0.05	-0.3	0.27	0.14	0.57	-0.68	0.32	-0.84	-0.85	-0.4	-0.81	0.83	0.51	-0.85	0.36	0.51	-0.74		-0.82	-0.88	0.7	0.57	0.91	-0.57	0.76	-0.83
Non Current Liabilities Total	0.13	0.01	-0.71	-0.51	-0.29	0.96	-0.06	0.99	0.93	0.23	0.99	-0.84	-0.83	0.99	-0.72	-0.83	0.91	-0.82		0.97	-0.9	-0.07	-0.88	0.3	-0.54	0.81
Capital Lease Obligations	0.05	0.17	-0.55	-0.32	-0.45	0.91	-0.22	0.98	0.96	0.38	0.94	-0.88	-0.82	0.98	-0.59	-0.82	0.87	-0.88	0.97		-0.85	-0.2	-0.91	0.49	-0.67	0.77
Inventory	-0.54	0.11	0.71	0.52	0.09	-0.93	-0.13	-0.91	-0.71	-0.05	-0.89	0.76	0.58	-0.91	0.75	0.58	-1.0	0.7	-0.9	-0.85		-0.18	0.62	-0.19	0.31	-0.67
Other Current Assets	0.46	-0.48	-0.48	-0.39	0.62	0.14	0.53	-0.09	-0.3	-0.41	-0.07	0.3	-0.06	-0.11	-0.34	-0.06	0.13	0.57	-0.07	-0.2	-0.18		0.5	-0.52	0.63	-0.33
Other Stockholder Equity	0.24	-0.22	0.42	0.28	0.54	-0.74	0.31	-0.87	-0.95	-0.41	-0.87	0.81	0.76	-0.88	0.45	0.76	-0.65	0.91	-0.88	-0.91	0.62	0.5		-0.46	0.75	-0.84
Total Liab	-0.29	0.91	0.41	0.67	-0.95	0.14	-0.91	0.32	0.57	0.92	0.2	-0.29	-0.31	0.32	0.4	-0.31	0.23	-0.57	0.3	0.49	-0.19	-0.52	-0.46		-0.91	0.27
Net Invested Capital	0.42	-0.81	-0.15	-0.4	0.96	-0.32	0.85	-0.52	-0.8	-0.89	-0.45	0.43	0.54	-0.53	-0.18	0.54	-0.35	0.76	-0.54	-0.67	0.31	0.63	0.75	-0.91		-0.58
Property Plant And Equipment Gross	-0.04	0.13	-0.54	-0.4	-0.38	0.67	-0.16	0.76	0.78	0.27	0.77	-0.61	-0.59	0.78	-0.45	-0.59	0.7	-0.83	0.81	0.77	-0.67	-0.33	-0.84	0.27	-0.58

Click cells to compare fundamentals

TC BioPharm Account Relationship Matchups

TC BioPharm fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	7.3M	8.0M	11.3M	8.9M	10.3M	10.0M
Short Long Term Debt Total	2.6M	15.9M	2.5M	1.8M	1.6M	1.5M
Other Current Liab	3.1M	9.6M	7.3M	2.5M	2.8M	5.1M
Total Current Liabilities	4.2M	20.6M	9.2M	4.8M	5.5M	9.4M
Total Stockholder Equity	(3.3M)	(16.6M)	331.3K	2.7M	3.1M	3.2M
Property Plant And Equipment Net	4.6M	3.7M	3.3M	2.6M	2.4M	3.2M
Net Debt	1.8M	14.3M	(2.4M)	(661.5K)	(595.3K)	(565.5K)
Retained Earnings	(19.9M)	(33.5M)	(33.4M)	(38.8M)	(35.0M)	(36.7M)
Accounts Payable	638.4K	1.4M	882.4K	1.8M	2.1M	1.2M
Cash	748.0K	1.6M	4.8M	2.5M	2.8M	2.3M
Non Current Assets Total	5.0M	4.2M	3.8M	3.2M	2.9M	3.6M
Cash And Short Term Investments	748.0K	1.6M	4.8M	2.5M	2.8M	2.3M
Net Receivables	1.2M	1.5M	1.8M	1.2M	1.1M	1.4M
Common Stock Shares Outstanding	11.2M	7.8M	13.7M	123.6M	142.1M	149.2M
Liabilities And Stockholders Equity	7.3M	8.0M	11.3M	8.9M	10.3M	10.0M
Non Current Liabilities Total	6.4M	4.0M	1.8M	1.5M	1.3M	1.3M
Capital Lease Obligations	3.0M	2.9M	2.1M	1.8M	1.6M	2.1M
Inventory	(1.2M)	(1.5M)	(1.8M)	(1.2M)	(1.4M)	(1.5M)
Other Current Assets	230.7K	811.3K	836.1K	4.1M	4.7M	4.9M
Other Stockholder Equity	(1.6M)	16.7M	33.7M	41.5M	47.7M	50.1M
Total Liab	10.6M	24.6M	11.0M	6.2M	5.6M	10.4M
Net Invested Capital	(3.3M)	(9.8M)	627.8K	2.7M	3.1M	3.2M
Property Plant And Equipment Gross	6.9M	6.7M	6.5M	6.8M	6.1M	5.4M
Total Current Assets	2.2M	3.9M	7.4M	5.7M	6.6M	5.2M
Capital Stock	1.8M	195.5K	397.5K	2.1K	1.9K	1.8K
Net Working Capital	(2.0M)	(16.7M)	(1.7M)	950.3K	1.1M	1.1M
Short Term Debt	442.7K	7.6M	981.5K	305.3K	351.1K	333.6K
Intangible Assets	423.8K	483.6K	553.0K	615.2K	707.4K	523.9K
Common Stock	194.6K	195.5K	397.5K	2.1K	1.9K	1.8K

Pair Trading with TC BioPharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.

Moving against TCBP Stock

0.79	OPT	Opthea	Pair Corr
0.76	PHGE	Biomx Inc	Pair Corr
0.71	FENC	Fennec Pharmaceuticals	Pair Corr
0.7	LTRN	Lantern Pharma	Pair Corr
0.65	GANX	Gain Therapeutics	Pair Corr

The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.

The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for TCBP Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC